![](jpg/gettyimages-1280895783-150x150.jpg)
artificial intelligence
-
Pharma, Artificial Intelligence, BioPharma
Novo Nordisk Turns to Flagship’s Valo Health for AI-Driven Cardio Drug R&D
Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.
-
Artificial Intelligence, BioPharma
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
MedCity Influencers, Artificial Intelligence, Health Tech
How Health Tech is Squashing AI Biases and Leveling the Playing Field in Healthcare
By making large amounts of diverse data widely available, healthcare institutions can feel confident about the evaluation, creation, and validation of algorithms as they’re transitioned from ideation to use.
-
Artificial Intelligence, BioPharma
Recursion Vets Unveil Startup Noetik, Using AI to Unlock Tumor Biology
By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.
-
MedCity Influencers, Health Tech
5 Ways NLP AI Technology is Driving Value for Providers Today
Don’t bet so big on AI solutions with “someday potential” that you ignore tools that can solve challenges and generate ROI now. Here are five critical AI investments that provide “right now” value for health systems, clinicians and patients.
-
MedCity Influencers, Artificial Intelligence
Prediction is Power: The Truth About What is AI, Really
Do some people simply think the A in AI stands for Automation? Most likely the confusion is due to a lack of understanding of what AI truly is, combined with a strong desire to use the term for marketing purposes.
-
VC Report: Biotech Financings Fall, M&A Activity Expected to Pick Up
Biotech startups raised $2.6 billion globally in the second quarter of this year, but that’s down nearly 46% compared to the same period last year, according to a report from Pitchbook. Capital is harder to find, and the report projects an uptick in M&A activity as companies run out of cash.
-
Devices & Diagnostics, Artificial Intelligence
FDA Clearance Spotlight: UltraSight
UltraSight, based in Israel, recently received a nod from the FDA to market its UltraSight AI Guidance product that can assist medical professionals without sonography experience in acquiring cardiac ultrasound images and allow for more widespread detection of heart diseases.
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Artificial Intelligence, BioPharma
Sumitomo Schizophrenia Drug Discovered With AI Tech Fails in Two Phase 3 Trials
A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from a psychiatry and neurology collaboration spanning four drugs discovered by an artificial intelligence technology platform.
-
Artificial Intelligence, BioPharma
Nvidia’s $50M Recursion Investment Starts Alliance to Scale Up in AI Drug Discovery
Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
-
The 3 Hottest Areas for Healthcare Generative AI
There are three key areas of the healthcare sector where generative AI is booming the most — in terms of both venture capital funding and the development of innovative technology — according to Anjalika Komatireddy, an analyst at CB Insights. During a recent webinar, she discussed the generative AI activity occurring in these three areas: care delivery and navigation, digital therapeutics and drug discovery.
-
MedCity Influencers, Artificial Intelligence
What Every Health System CFO Needs to Know Before Using AI for Medical Coding
With few workers entering a field dominated by older Gen X-ers and Baby Boomers, there’s a growing gap in skilled medical coders — people who read notes from doctors and apply appropriate codes for billing and reimbursement purposes. So many are turning to AI.
-
Devices & Diagnostics, Health Tech
Eyenuk’s New FDA Clearance Could Boost Adoption for Its Diabetic Retinopathy Screening Tech
Eyenuk recently received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system, which automatically detects diabetic retinopathy. The company said this FDA clearance makes its system the only AI system that is FDA-cleared for use with multiple retinal cameras produced by different manufacturers.
-
The Missing Ingredients to Build Successful Enterprise AI Strategies in Healthcare
Losing sight of organizational goals and priorities and operating without a clear, supported plan can lead to a scatter-shot approach to AI investment that may duplicate investments, misallocate resources, and cause stakeholders to become cynical about AI’s value and potential.